Denosumab is one of the human monoclonal antibodies targeting RANKL, a potent inhibitor of osteoclast activity and differentiation and is used in the treatment of osteoporosis and bone metastasis (Cummings et al., 2009; Delmas, 2008). Here, TNFSF11 is linked to osteoporosis.